Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 68
Filtrar
1.
Blood ; 140(5): 419-437, 2022 08 04.
Artigo em Inglês | MEDLINE | ID: mdl-34758074

RESUMO

The number of patients with primary cutaneous lymphoma (PCL) relative to other non-Hodgkin lymphomas (NHLs) is small and the number of subtypes large. Although clinical trial guidelines have been published for mycosis fungoides/Sézary syndrome, the most common type of PCL, none exist for the other PCLs. In addition, staging of the PCLs has been evolving based on new data on potential prognostic factors, diagnosis, and assessment methods of both skin and extracutaneous disease and a desire to align the latter with the Lugano guidelines for all NHLs. The International Society for Cutaneous Lymphomas (ISCL), the United States Cutaneous LymphomaConsortium (USCLC), and the Cutaneous Lymphoma Task Force of the European Organization for the Research and Treatment of Cancer (EORTC) now propose updated staging and guidelines for the study design, assessment, endpoints, and response criteria in clinical trials for all the PCLs in alignment with that of the Lugano guidelines. These recommendations provide standardized methodology that should facilitate planning and regulatory approval of new treatments for these lymphomas worldwide, encourage cooperative investigator-initiated trials, and help to assess the comparative efficacy of therapeutic agents tested across sites and studies.


Assuntos
Linfoma Cutâneo de Células T , Micose Fungoide , Síndrome de Sézary , Neoplasias Cutâneas , Ensaios Clínicos como Assunto , Humanos , Linfoma Cutâneo de Células T/diagnóstico , Linfoma Cutâneo de Células T/patologia , Linfoma Cutâneo de Células T/terapia , Micose Fungoide/diagnóstico , Micose Fungoide/patologia , Micose Fungoide/terapia , Estadiamento de Neoplasias , Síndrome de Sézary/diagnóstico , Síndrome de Sézary/patologia , Síndrome de Sézary/terapia , Neoplasias Cutâneas/diagnóstico , Neoplasias Cutâneas/patologia , Neoplasias Cutâneas/terapia , Estados Unidos
2.
J Natl Compr Canc Netw ; 20(3): 285-308, 2022 03.
Artigo em Inglês | MEDLINE | ID: mdl-35276674

RESUMO

Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphoproliferative disorders arising from mature T cells, accounting for about 10% of non-Hodgkin lymphomas. PTCL-not otherwise specified is the most common subtype, followed by angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma, anaplastic lymphoma kinase-positive, anaplastic large cell lymphoma, anaplastic lymphoma kinase-negative, and enteropathy-associated T-cell lymphoma. This discussion section focuses on the diagnosis and treatment of PTCLs as outlined in the NCCN Guidelines for T-Cell Lymphomas.


Assuntos
Linfadenopatia Imunoblástica , Linfoma de Células T Periférico , Linfoma de Células T , Humanos , Linfadenopatia Imunoblástica/diagnóstico , Linfadenopatia Imunoblástica/patologia , Linfadenopatia Imunoblástica/terapia , Linfoma de Células T/diagnóstico , Linfoma de Células T/terapia , Linfoma de Células T Periférico/diagnóstico , Linfoma de Células T Periférico/terapia
3.
J Natl Compr Canc Netw ; 18(11): 1460-1467, 2020 11 02.
Artigo em Inglês | MEDLINE | ID: mdl-33152703

RESUMO

Hepatosplenic T-cell lymphoma (HSTCL) is a rare subtype of T-cell lymphoma associated with an aggressive clinical course and a worse prognosis. HSTCL develops in the setting of chronic immune suppression or immune dysregulation in up to 20% of cases and is most often characterized by spleen, liver, and bone marrow involvement. Diagnosis and management of HSTCL pose significant challenges given the rarity of the disease along with the absence of lymphadenopathy and poor outcome with conventional chemotherapy regimens. These Guidelines Insights focus on the diagnosis and treatment of HSTCL as outlined in the NCCN Guidelines for T-Cell Lymphomas.


Assuntos
Linfoma de Células T , Humanos , Linfoma de Células T/diagnóstico , Linfoma de Células T/epidemiologia , Linfoma de Células T/terapia , Guias de Prática Clínica como Assunto , Prognóstico
4.
J Natl Compr Canc Netw ; 18(5): 522-536, 2020 05.
Artigo em Inglês | MEDLINE | ID: mdl-32380458

RESUMO

Mycosis fungoides (MF) is the most common subtype of cutaneous T-cell lymphoma (CTCL), and Sézary syndrome (SS) is a rare erythrodermic and leukemic subtype of CTCL characterized by significant blood involvement. Although early-stage disease can be effectively treated predominantly with skin-directed therapies, systemic therapy is often necessary for the treatment of advanced-stage disease. Systemic therapy options have evolved in recent years with the approval of novel agents such as romidepsin, brentuximab vedotin, and mogamulizumab. These NCCN Guidelines Insights discuss the diagnosis and management of MF and SS (with a focus on systemic therapy).


Assuntos
Linfoma Cutâneo de Células T/patologia , Micose Fungoide/diagnóstico , Neoplasias Cutâneas/patologia , Guias como Assunto , Humanos , Micose Fungoide/patologia
5.
J Am Acad Dermatol ; 82(2): 412-419, 2020 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-31622643

RESUMO

BACKGROUND: There are currently no treatments for alopecia areata (AA) that are universally effective or approved by the US Food and Drug Administration. Oral ruxolitinib has shown efficacy in extensive AA. Ruxolitinib cream would potentially avoid systemic adverse effects. OBJECTIVE: To assess the efficacy and safety of 1.5% ruxolitinib cream in patients with AA who had at least 25% hair loss by Severity of Alopecia Tool score. METHODS: This was a 2-part study. Part A was an open-label, 24-week study of 1.5% ruxolitinib cream in patients with 25% to 99% hair loss followed by a 24-week extension period. Part B was a double-blind, vehicle-controlled, 24-week study of 1.5% ruxolitinib cream in patients with 25% to 100% hair loss, followed by a crossover to ruxolitinib cream in the vehicle group for 24 weeks and additional treatment time for the ruxolitinib cream group. RESULTS: Although Part A results suggested potential efficacy of 1.5% ruxolitinib cream, there was no significant difference in hair regrowth based on 50% improvement in Severity of Alopecia Tool scores between patients receiving 1.5% ruxolitinib cream and vehicle in part B. There were no significant safety issues with 1.5% ruxolitinib cream. LIMITATIONS: Single strength of ruxolitinib cream. CONCLUSIONS: The 1.5% ruxolitinib cream did not have a significant effect in patients with AA.


Assuntos
Alopecia em Áreas/tratamento farmacológico , Pirazóis/administração & dosagem , Adolescente , Adulto , Idoso , Método Duplo-Cego , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Nitrilas , Veículos Farmacêuticos , Pirazóis/efeitos adversos , Pirimidinas , Índice de Gravidade de Doença , Creme para a Pele , Resultado do Tratamento , Adulto Jovem
6.
J Am Acad Dermatol ; 80(6): 1538-1543.e1, 2019 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-29017840

RESUMO

BACKGROUND: Focal atrichia is a common clinical finding in female pattern hair loss, the specificity and histologic findings of which need further clarification. OBJECTIVE: To determine the frequency of focal atrichia in various types of hair loss and its histologic characteristics in female pattern hair loss. METHODS: Part 1 of the study was a review of 250 consecutive female patients seen with hair loss for the presence of focal atrichia, and part 2 examined paired biopsy specimens from haired areas versus those from areas with focal atrichia in 18 subjects with female pattern hair loss. RESULTS: Focal atrichia was seen in 46 of 104 of women with female pattern hair loss (44%), including 67% of those with the late-onset subtype versus 15% of those with the early-onset subtype, compared with in 3 of 146 of those with other hair disorders (2%). Biopsy findings of focal atrichia in female pattern hair loss showed primarily a more progressive miniaturization process than that of haired areas of the scalp. LIMITATIONS: Some women with female pattern hair loss may have had concomitant chronic telogen effluvium. CONCLUSIONS: When present, focal atrichia is a clinical clue to the diagnosis of female pattern hair loss, particularly the late-onset subtype.


Assuntos
Alopecia/patologia , Folículo Piloso/patologia , Adolescente , Adulto , Idoso , Alopecia/diagnóstico , Biópsia , Feminino , Humanos , Pessoa de Meia-Idade , Adulto Jovem
8.
J Natl Compr Canc Netw ; 16(2): 123-135, 2018 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-29439173

RESUMO

Natural killer (NK)/T-cell lymphomas are a rare and distinct subtype of non-Hodgkin's lymphomas. NK/T-cell lymphomas are predominantly extranodal and most of these are nasal type, often localized to the upper aerodigestive tract. Because extranodal NK/T-cell lymphomas (ENKL) are rare malignancies, randomized trials comparing different regimens have not been conducted to date and standard therapy has not yet been established for these patients. These NCCN Guidelines Insights discuss the recommendations for the diagnosis and management of patients with ENKL as outlined in the NCCN Guidelines for T-Cell Lymphomas.


Assuntos
Linfoma de Células T/diagnóstico , Linfoma de Células T/terapia , Gerenciamento Clínico , Humanos , Linfoma de Células T/etiologia
9.
J Am Acad Dermatol ; 79(3): 470-478.e3, 2018 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-29128463

RESUMO

BACKGROUND: Although alopecia areata is a common disorder, it has no US Food and Drug Administration-approved treatment and evidence-based therapeutic data are lacking. OBJECTIVE: To develop guidelines for the diagnosis, evaluation, assessment, response criteria, and end points for alopecia areata. METHODS: Literature review and expert opinion of a group of dermatologists specializing in hair disorders. RESULTS: Standardized methods of assessing and tracking hair loss and growth, including new scoring techniques, response criteria, and end points in alopecia areata are presented. LIMITATIONS: The additional time to perform the assessments is the primary limitation to use of the methodology in clinical practice. CONCLUSION: Use of these measures will facilitate collection of standardized outcome data on therapeutic agents used in alopecia areata both in clinical practice and in clinical trials.


Assuntos
Alopecia em Áreas/diagnóstico , Cabelo/crescimento & desenvolvimento , Avaliação de Resultados em Cuidados de Saúde/métodos , Guias de Prática Clínica como Assunto , Alopecia em Áreas/tratamento farmacológico , Coleta de Dados , Autoavaliação Diagnóstica , Determinação de Ponto Final , Humanos , Índice de Gravidade de Doença
10.
Mod Pathol ; 30(5): 761-772, 2017 05.
Artigo em Inglês | MEDLINE | ID: mdl-28128277

RESUMO

Primary cutaneous CD8-positive aggressive epidermotropic T-cell lymphoma is a rare and poorly characterized variant of cutaneous lymphoma still considered a provisional entity in the latest 2016 World Health Organization Classification of Cutaneous lymphomas. We sought to better characterize and provide diagnostic and therapeutic guidance of this rare cutaneous lymphoma. Thirty-four patients with a median age of 77 years (range 19-89 years) presented primarily with extensive annular necrotic plaques or tumor lesions with frequent mucous membrane involvement. The 5-year survival was 32% with a median survival of 12 months. A subset of 17 patients had a prodrome of chronic patches prior to the development of aggressive ulcerative lesions. We identified cases with lack of CD8 or αß T-cell receptor expression yet with similar clinical and pathological presentation. Allogeneic stem cell transplantation provided partial or complete remissions in 5/6 patients. We recommend the term primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphoma as this more broad designation better describes this clinical-pathologic presentation, which allows the inclusion of cases with CD8 negative and/or αß/γδ T-cell receptor chain double-positive or double-negative expression. We have identified early skin signs of chronic patch/plaque lesions that are often misdiagnosed as eczema, psoriasis, or mycosis fungoides. Our experience confirms the poor prognosis of this entity and highlights the inefficacy of our standard therapies with the exception of allogeneic stem cell transplantation in selected cases.


Assuntos
Linfoma Cutâneo de Células T , Neoplasias Cutâneas , Linfócitos T Citotóxicos/patologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Organização Mundial da Saúde , Adulto Jovem
11.
J Natl Compr Canc Netw ; 14(5): 574-97, 2016 05.
Artigo em Inglês | MEDLINE | ID: mdl-27160235

RESUMO

Basal cell carcinoma (BCC) of the skin is the most common cancer, with a higher incidence than all other malignancies combined. Although it is rare to metastasize, patients with multiple or frequently recurring BCC can suffer substantial comorbidity and be difficult to manage. Assessment of risk is a key element of management needed to inform treatment selection. The overall management of BCC primarily consists of surgical approaches, with radiation therapy as an alternate or adjuvant option. Many superficial therapies for BCC have been explored and continue to be developed, including topicals, cryosurgery, and photodynamic therapy. Two hedgehog pathway inhibitors were recently approved by the FDA for systemic treatment of advanced and metastatic BCC, and others are in development. The NCCN Guidelines for Basal Cell Skin Cancer, published in full herein, include recommendations for selecting among the various surgical approaches based on patient-, lesion-, and disease-specific factors, as well as guidance on when to use radiation therapy, superficial therapies, and hedgehog pathway inhibitors.


Assuntos
Carcinoma Basocelular , Neoplasias Cutâneas , Humanos , Carcinoma Basocelular/diagnóstico , Carcinoma Basocelular/terapia , Neoplasias Cutâneas/diagnóstico , Neoplasias Cutâneas/terapia , Estados Unidos
12.
J Am Acad Dermatol ; 74(1): 27-58, 2016 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-26547257

RESUMO

BACKGROUND: Ultraviolet light (UVL) is a long established treatment for mycosis fungoides (MF) and Sézary syndrome (SS), subtypes of cutaneous T-cell lymphoma (CTCL). Treatments have traditionally included broadband, narrowband ultraviolet B light (UVB) and psoralen plus ultraviolet A light photochemotherapy (PUVA), but more recently, treatment options have expanded to include UVA1 and excimer laser. UVL is used either as monotherapy or as an adjuvant to systemic therapy, demonstrating efficacy in many cases that equal or surpass systemic medications. Despite its utility and duration of use, the current practice of using UVL guidelines for psoriasis to treat patients with MF/SS is problematic because the goals of prolonging survival and preventing disease progression are unique to CTCL compared to psoriasis. OBJECTIVES: We sought to develop separate guidelines for phototherapy for MF/SS for both clinical practice and for clinical trials. METHODS: Literature review and cutaneous lymphoma expert consensus group recommendations. RESULTS: This paper reviews the published literature for UVB and UVA/PUVA in MF/SS and suggests practical standardized guidelines for their use. LIMITATIONS: New standardization of phototherapy. CONCLUSIONS: These guidelines should allow the comparison of results with phototherapy in MF/SS across different stages of patients, centers, and in combination with other agents in practice and in clinical trials.


Assuntos
Micose Fungoide/terapia , Fototerapia/métodos , Guias de Prática Clínica como Assunto , Síndrome de Sézary/terapia , Neoplasias Cutâneas/terapia , Feminino , Humanos , Masculino , Micose Fungoide/diagnóstico , Terapia PUVA/métodos , Prognóstico , Medição de Risco , Síndrome de Sézary/diagnóstico , Neoplasias Cutâneas/diagnóstico , Sociedades Médicas , Resultado do Tratamento , Terapia Ultravioleta/métodos , Estados Unidos
13.
J Drugs Dermatol ; 15(7): 883-9, 2016 Jul 01.
Artigo em Inglês | MEDLINE | ID: mdl-27391640

RESUMO

BACKGROUND: A once-daily minoxidil topical foam (MTF) has been developed to treat female pattern hair loss.
OBJECTIVE: Determine noninferiority of once-daily 5% MTF versus twice-daily 2% minoxidil topical solution (MTS) based on the change from baseline in target area hair count (TAHC) at 24 weeks. METHODS: In a randomized, phase III trial, women with female pattern hair loss received once-daily 5% MTF (n=161) or twice-daily 2% MTS (n=161) for 52 weeks. Primary endpoint was change from baseline in TAHC at 24 weeks. Secondary endpoint was change from baseline in TAHC at 12 weeks. Exploratory endpoints included change in total unit area density and change in overall scalp coverage.
RESULTS: Once-daily 5% MTF increased TAHC from baseline (adjusted mean ± standard error) by 23.9 ± 2.1 hairs/cm2 at week 24. Twice-daily 2% MTS increased TAHC 24.2 ± 2.1 hairs/cm2 at week 24. The treatment difference was -0.3 hairs/cm2 (95% CI = -6.0, 5.4). Since the lower bound of the 95% CI was less than -5.0, the prespecified noninferiority goal was not met. Both treatments were well tolerated.
CONCLUSIONS: Once-daily 5% MTF and twice-daily 2% MTS induced hair regrowth in female pattern hair loss, but prespecified noninferiority criteria were not met.
ClinicalTrials.gov identifier: NCT01145625

J Drugs Dermatol. 2016;15(7):883-889.


Assuntos
Alopecia/diagnóstico , Alopecia/tratamento farmacológico , Minoxidil/administração & dosagem , Minoxidil/química , Adulto , Idoso , Dermatite Irritante/diagnóstico , Dermatite Irritante/etiologia , Esquema de Medicação , Composição de Medicamentos , Feminino , Humanos , Pessoa de Meia-Idade , Minoxidil/efeitos adversos , Soluções Farmacêuticas/administração & dosagem , Soluções Farmacêuticas/efeitos adversos , Soluções Farmacêuticas/química , Método Simples-Cego , Resultado do Tratamento
14.
J Am Acad Dermatol ; 83(2): 703-704, 2020 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-32305443
15.
J Am Acad Dermatol ; 68(5): 749-55, 2013 May.
Artigo em Inglês | MEDLINE | ID: mdl-23375454

RESUMO

BACKGROUND: Frontal fibrosing alopecia (FFA) is a type of scarring hair loss primarily observed in postmenopausal women and characterized by fronto-tempero-parietal hairline recession, perifollicular erythema, and loss of eyebrows. The incidence is unknown, but the number of women presenting with this condition has significantly increased in recent years. No effective therapy has been established. OBJECTIVE: The purpose of this study is to present pertinent demographic and clinical findings of patients with FFA seen at an academic hair loss clinic and their responses to various therapeutic interventions. METHODS: Patients seen at the Duke University Hair Disorders Research and Treatment Center, Durham, NC, between 2004 and 2011 who met FFA inclusion criteria and signed an informed consent form for participation in the Duke University Hair Disorders Research and Treatment Center database were included in this review. RESULTS: Nineteen female patients with FFA met our inclusion criteria, the majority of whom were white and postmenopausal. A number of treatments, including topical and intralesional steroids, antibiotics, and immunomodulators, were used with disappointing results in most patients. However, the majority of patients on dutasteride experienced disease stabilization. LIMITATIONS: This was a retrospective review and outside clinic records were occasionally incomplete. CONCLUSIONS: FFA is an increasingly common form of scarring hair loss, but the origin remains unknown. Without clear understanding of the pathogenesis and evolution of this condition, it is not surprising that treatments to date have been minimally or not effective. At our institution, dutasteride was most effective in halting disease progression, although no therapy was associated with significant hair regrowth.


Assuntos
Alopecia/tratamento farmacológico , Alopecia/patologia , Azasteroides/uso terapêutico , Líquen Plano/tratamento farmacológico , Líquen Plano/patologia , Inibidores de 5-alfa Redutase/uso terapêutico , Adulto , Idoso , Antibacterianos/uso terapêutico , Cicatriz/tratamento farmacológico , Cicatriz/patologia , Dutasterida , Inibidores Enzimáticos/uso terapêutico , Sobrancelhas/patologia , Feminino , Fibrose , Testa/irrigação sanguínea , Testa/patologia , Hospitais Universitários , Humanos , Hidroxicloroquina/uso terapêutico , Imunossupressores , Metotrexato/uso terapêutico , Pessoa de Meia-Idade , Minociclina/uso terapêutico , Osteoporose Pós-Menopausa , Estudos Retrospectivos , Couro Cabeludo/irrigação sanguínea , Couro Cabeludo/patologia , Tacrolimo/uso terapêutico , Resultado do Tratamento
16.
J Am Acad Dermatol ; 67(3): 379-86, 2012 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-22325459

RESUMO

BACKGROUND: Finasteride (1 mg) has been shown to increase vertex hair growth in men aged 18 to 60 years with male pattern hair loss and to increase frontal scalp hair growth in subjects aged 18 to 41 years. OBJECTIVE: A secondary efficacy analysis was conducted to determine effects of finasteride (1 mg) on scalp hair growth in the 4 distinct scalp regions affected by male pattern hair loss. METHODS: Multicenter, double-blind studies randomized patients with vertex hair loss (men aged 18-41 and 41-60 years) to finasteride (1 mg/d) or placebo. Efficacy was evaluated by review of standardized clinical photographs (global photographic assessment) of the vertex, anterior/mid scalp regions, and frontal and temporal hairlines over 24 months relative to baseline. RESULTS: At 24 months, treatment with finasteride resulted in statistically significant (P ≤ .05) hair growth versus placebo in all scalp regions. There was also a significant decrease in hair loss in the younger men treated with finasteride in all areas, but only in the vertex and anterior/mid scalp regions in the older men. A slightly higher incidence of drug-related sexual adverse experiences was reported in the finasteride group than in the placebo group, irrespective of age. LIMITATIONS: These studies enrolled men with vertex pattern hair loss; therefore, the findings may not be extrapolated to men with predominantly anterior/mid scalp, frontal, or temporal hair loss. CONCLUSION: Based on global photographic assessment, finasteride (1 mg) is able to increase hair growth in all areas of the scalp affected by male pattern hair loss.


Assuntos
Inibidores de 5-alfa Redutase/administração & dosagem , Alopecia/tratamento farmacológico , Finasterida/administração & dosagem , Adolescente , Adulto , Humanos , Análise de Intenção de Tratamento , Masculino , Pessoa de Meia-Idade , Fotografação , Resultado do Tratamento , Adulto Jovem
17.
J Am Acad Dermatol ; 67(5): 1025-39, 2012 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-22502948

RESUMO

Dermatologic adverse events to cancer therapies have become more prevalent and may to lead to dose modifications or discontinuation of life-saving or prolonging treatments. This has resulted in a new collaboration between oncologists and dermatologists, which requires accurate cataloging and grading of side effects. The Common Terminology Criteria for Adverse Events Version 4.0 is a descriptive terminology and grading system that can be used for uniform reporting of adverse events. A proper understanding of this standardized classification system is essential for dermatologists to properly communicate with all physicians caring for patients with cancer.


Assuntos
Antineoplásicos/efeitos adversos , Dermatopatias/induzido quimicamente , Dermatopatias/classificação , Terminologia como Assunto , Erupções Acneiformes/induzido quimicamente , Atividades Cotidianas , Dermatite Esfoliativa/induzido quimicamente , Dicionários como Assunto , Receptores ErbB/antagonistas & inibidores , Doenças do Cabelo/induzido quimicamente , Humanos , Neoplasias/tratamento farmacológico , Paroniquia/induzido quimicamente , Síndrome de Stevens-Johnson/induzido quimicamente , Síndrome de Stevens-Johnson/etiologia
19.
J Am Acad Dermatol ; 64(2): 245-52, 2011 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-21075478

RESUMO

BACKGROUND: Although central scalp hair loss is a common problem in African American women, data on etiology or incidence are limited. OBJECTIVE: We sought to determine the frequency of various patterns and degree of central scalp hair loss in African American women and to correlate this with information on hair care practices, family history of hair loss, and medical history. METHODS: Five hundred twenty-nine subjects at six different workshops held at four different sites in the central and/or southeast United States participated in this study. The subjects' patterns and degree of central scalp hair loss were independently assessed by both subject and investigator using a standardized photographic scale. Subjects also completed a detailed questionnaire and had standardized photographs taken. Statistical analysis was performed evaluating answers to the questionnaire relative to pattern of central hair loss. RESULTS: Extensive central scalp hair loss was seen in 5.6% of subjects. There was no obvious association of extensive hair loss with relaxer or hot comb use, history of seborrheic dermatitis or reaction to a hair care product, bacterial infection, or male pattern hair loss in fathers of subjects; however, there was an association with a history of tinea capitis. LIMITATIONS: There was no scalp biopsy correlation with clinical pattern of hair loss and further information on specifics of hair care practices is needed. CONCLUSIONS: This central scalp photographic scale and questionnaire provide a valid template by which to further explore potential etiologic factors and relationships to central scalp hair loss in African American women.


Assuntos
Alopecia/etiologia , Negro ou Afro-Americano/estatística & dados numéricos , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Alopecia/classificação , Alopecia/epidemiologia , Alopecia/genética , Pai , Feminino , Preparações para Cabelo/efeitos adversos , Humanos , Hiperandrogenismo/complicações , Masculino , Pessoa de Meia-Idade , Mães , Fotografação/normas , Sudeste dos Estados Unidos
20.
J Am Acad Dermatol ; 64(2): 352-404, 2011 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-21145619

RESUMO

Sézary syndrome (SS) has a poor prognosis and few guidelines for optimizing therapy. The US Cutaneous Lymphoma Consortium, to improve clinical care of patients with SS and encourage controlled clinical trials of promising treatments, undertook a review of the published literature on therapeutic options for SS. An overview of the immunopathogenesis and standardized review of potential current treatment options for SS including metabolism, mechanism of action, overall efficacy in mycosis fungoides and SS, and common or concerning adverse effects is first discussed. The specific efficacy of each treatment for SS, both as monotherapy and combination therapy, is then reported using standardized criteria for both SS and response to therapy with the type of study defined by a modification of the US Preventive Services guidelines for evidence-based medicine. Finally, guidelines for the treatment of SS and suggestions for adjuvant treatment are noted.


Assuntos
Síndrome de Sézary/patologia , Síndrome de Sézary/terapia , Neoplasias Cutâneas/patologia , Neoplasias Cutâneas/terapia , Alquilantes/uso terapêutico , Anticorpos Monoclonais/uso terapêutico , Antineoplásicos/uso terapêutico , Ensaios Clínicos como Assunto , Terapia Combinada , Quimioterapia Combinada , Medicina Baseada em Evidências , Inibidores de Histona Desacetilases/uso terapêutico , Humanos , Fatores Imunológicos/uso terapêutico , Metotrexato/uso terapêutico , Micose Fungoide/patologia , Micose Fungoide/terapia , Qualidade de Vida , Retinoides/uso terapêutico , Síndrome de Sézary/imunologia , Neoplasias Cutâneas/imunologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA